Description
Tesamorelin / Ipamorelin
Dual-Pathway GH Secretagogue Stack
Two growth-hormone secretagogues in a single vial — a GHRH analog and a selective ghrelin mimetic — engaging both pituitary GH-release pathways at once for a larger, cleaner pulse than either peptide achieves alone.
Two signals, one pulse — build the factory, then empty the warehouse.
| This blend pairs two complementary growth-hormone secretagogues. Tesamorelin, a 44-amino acid GHRH analog, signals the pituitary to produce and release growth hormone — building capacity. Ipamorelin, a selective ghrelin-receptor pentapeptide, triggers an immediate release of stored GH while lifting the somatostatin brake that normally limits the pulse.
Because the two act through different receptors, their effects combine rather than overlap. At Guardian Labs, both peptides are supplied together as a research-grade lyophilized powder, HPLC-verified above ninety-nine percent purity and lot-verified for consistent ratios across your GH-axis and metabolic investigations. |
Recruiting the GHRH and ghrelin pathways together engages more somatotrophs releasing more GH per cell — with the somatostatin brake released — producing a synergistic pulse that exceeds either peptide alone.
|
Four coordinated steps — from two receptors to one IGF-1 output.
i
GHRH SignalTesamorelin binds GHRH receptors on pituitary somatotrophs, driving production and pulsatile release of growth hormone — the “build the factory” signal. |
ii
Ghrelin SignalIpamorelin selectively activates the GHS-R1a (ghrelin) receptor, prompting an immediate release of stored GH — the “empty the warehouse” signal. |
iii
Brake RemovalIpamorelin also suppresses somatostatin, the body’s natural “off switch” for GH — lifting the brake and amplifying the height of the combined pulse. |
iv
IGF-1 OutputThe elevated GH pulse acts on the liver to raise IGF-1 — the downstream mediator behind tissue repair, body-composition, and recovery signaling. |
On Selectivity
Ipamorelin is prized for its clean profile: unlike GHRP-2 or GHRP-6, it does not meaningfully raise cortisol, prolactin, or ACTH even at high doses. Pairing it with tesamorelin’s GHRH signal delivers a two-pathway pulse without the off-target hormone drift seen with less selective secretagogues — the reason this combination is a benchmark GH-axis research stack.
Two peptides, disclosed — content per vial.
10 mg
TesamorelinGHRH Analog · 44 Amino Acids A stabilized analog of growth hormone-releasing hormone, modified with a trans-3-hexenoic acid group to resist DPP-4 degradation. The FDA-approved GH-releasing factor (Egrifta) studied most rigorously for visceral adipose reduction. Preserves the body’s natural pulsatile GH release. |
5 mg
IpamorelinSelective Ghrelin Mimetic · Pentapeptide A five-amino acid selective agonist of the ghrelin / GH-secretagogue receptor. Triggers a rapid, targeted GH release without stimulating cortisol, prolactin, or ACTH — the most selective of the common GH secretagogues, and the cleanest partner for a GHRH analog. |
Primary subjects of investigation — strictly laboratory use.
A.01
GH Axis & IGF-1Studies of pulsatile growth-hormone release, somatotroph recruitment, and downstream IGF-1 dynamics under dual-pathway stimulation. |
A.02
Body CompositionResearch into visceral adipose reduction and lean-mass preservation, drawing on tesamorelin’s clinical fat-reduction endpoints. |
A.03
Recovery & TissueInvestigating GH/IGF-1 contributions to connective-tissue repair, collagen turnover, and recovery in metabolic models. |
A.04
Metabolic & SleepExamining GH-axis effects on lipid metabolism, glucose handling, and sleep-associated GH pulse architecture. |
Peer-reviewed literature supporting the research potential of these peptides.
| i. |
Tesamorelin & Visceral Adipose TissueA large randomized controlled trial in adults with HIV-associated lipodystrophy reporting significant reductions in visceral fat and triglycerides over 26 weeks of daily tesamorelin, with lean mass preserved and glucose not worsened. |
View on PubMed → |
| ii. |
Ipamorelin & Selective GH ReleaseA foundational pharmacology study characterizing ipamorelin as a potent, selective GH secretagogue that raises growth hormone without stimulating ACTH or cortisol — distinguishing it from earlier GHRP peptides. |
View on PubMed → |
| iii. |
Tesamorelin & Hepatic FatA randomized trial reporting that tesamorelin reduced hepatic fat and slowed fibrosis progression in participants with NAFLD, extending its metabolic relevance beyond visceral adipose tissue. |
View on PubMed → |
| iv. |
GHRH + Ghrelin Pathway SynergyResearch demonstrating that co-stimulating the GHRH and ghrelin receptors produces a greater growth-hormone response than either pathway alone — the mechanistic basis for pairing a GHRH analog with a ghrelin mimetic. |
View on PubMed → |
Certificate of analysis available upon request.
| Blend Name | Tesamorelin / Ipamorelin |
| Composition | Dual GH-Secretagogue Stack (GHRH + Ghrelin) |
| Total Peptide | 15 mg per vial · 10 mg Tesamorelin + 5 mg Ipamorelin |
| Tesamorelin | C₂₂₁H₃₆₆N₇₂O₆₇S · 5135.85 g/mol · CAS 218949-48-5 |
| Ipamorelin | C₃₈H₄₉N₉O₅ · 711.85 g/mol · CAS 170851-70-4 |
| Format | Lyophilized Powder (Freeze-dried) |
| Purity | > 99% (HPLC Verified) |
| Storage — Unreconstituted | Store at −20°C · Protect from light |
| Storage — Reconstituted | Controlled room temperature (68–77°F) · Use within 7 days |
| Reconstitution | Bacteriostatic Water |
All products listed are intended exclusively for laboratory research and development purposes. They are not intended for human consumption, diagnostic, or therapeutic use. Customers must be at least 21 years of age to purchase.
Reviews
There are no reviews yet.